Biotinylated Human B7-2 / CD86 Protein, Fc,Avitag™, premium grade
分子别名(Synonym)
CD86,B7-2,B70,CD28LG2,LAB72,MGC34413
表达区间及表达系统(Source)
Biotinylated Human B7-2, Fc,Avitag, premium grade (CD6-H82F5) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # P42081).
Predicted N-terminus: Leu 26
该产品是在我们严格的质量控制体系下生产的,该体系包含一套全面的测试,包括无菌和内毒素测试。在早期临床前阶段,产品性能经过仔细验证和测试,以确保其与细胞培养用途或任何其他应用的兼容性。当准备过渡到后期临床阶段时,我们还提供定制的GMP蛋白质服务,以满足您的需求。我们将与您合作,根据您的要求定制和开发GMP级产品,该产品也符合细胞疗法细胞制造中使用的原材料和辅助材料的要求。
蛋白结构(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 53.8 kDa. The protein migrates as 66-90 kDa under reducing (R) condition, and 130-150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
标记(Labeling)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative.
纯度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
分化簇86(CD86)也称为B淋巴细胞活化抗原B7-2,是一种I型膜蛋白,是免疫球蛋白超家族的成员,在交叉树突细胞、朗格罕斯细胞、外周血树突细胞、记忆B细胞和生发中心B细胞上组成型表达。此外,B72在单核细胞上的表达水平较低,可以通过干扰素γ上调。CD86是T细胞表面两种不同蛋白质的配体:CD28(用于自动调节和细胞间结合)和CTLA-4(用于减弱调节和细胞分离)。CD86与CD80协同作用以激活T细胞。最近的研究表明,B7-2促进了成熟APC库的产生,并促进了APC的功能和存活。此外,B7蛋白还通过激活巨噬细胞中的NF-κB信号通路参与先天免疫反应。因此,CD86被视为免疫治疗的有前景的候选者。霍奇金淋巴瘤患者的CD86+巨噬细胞是一线治疗潜在无反应的独立标志物。